 | Up a level |
Jump to: 2023
Number of items: 1.
2023
Kutsch, Nadine, Holmes, Emily Eva, Robrecht, Sandra, Schueler, Gudrun, Vehling-Kaiser, Ursula, Decker, Thomas, Mueller-Hagen, Sigrun, Heinisch, Karin, Boettcher, Sebastian, Ritgen, Matthias, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Fink, Anna Maria, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Wendtner, Clemens-Martin (2023). Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients. Leuk. Lymphoma, 64 (2). S. 478 - 483. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403